Mealey's (September 30, 2022, 1:49 PM EDT) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals ruled Sept. 29 that the Patent Trial and Appeal Board correctly confirmed as patentable various claims of a patent claiming sitagliptin dihydrogen phosphate, the active substance of the diabetes drug Januvia....